Standard Chemotherapy for Myelomatosis: An Area of Great Controversy
- 1 April 1992
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 6 (2), 371-382
- https://doi.org/10.1016/s0889-8588(18)30350-2
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myelomaBlut: Zeitschrift für die Gesamte Blutforschung, 1990
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?European Journal of Cancer and Clinical Oncology, 1989
- Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMPEuropean Journal of Cancer and Clinical Oncology, 1988
- Short Course Intermediate Dose Intravenous Melphalan Therapy in Myeloma Relation to Early Emergence of Drug Resistance (Phase II Study)Acta Haematologica, 1987
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- Treatment of multiple myeloma with M-2 protocol and without maintenance therapyEuropean Journal of Cancer and Clinical Oncology, 1983
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaNew England Journal of Medicine, 1979